Managing Daraxonrasib: Key Takeaways and Efficacy Insights for Oncology Nurses

For Yolanda Justal, APRN, of the University of Miami Sylvester Comprehensive Cancer Center, the Aug. 26 FDA approval of daraxonrasib (Rasonque; Revolution Medicines, Inc.) brought profound professional validation. Justal, who managed patients on the pivotal Phase 3 RASolute 302 trial, watched clinical turnarounds she had rarely seen in her career. "[The] approval just culminated all of our hard work," Justal reflected in an interview with Oncology Nursing News. "The excitement had been building as we were enrolling patients and noticing they were faring better, having better quality of lives, and living longer."